DeepCure utilizes its Inspired Chemistry™ platform for automated chemical synthesis to develop small molecule therapies targeting autoimmune diseases, including rheumatoid arthritis and atopic dermatitis. By collaborating with leading researchers, the company aims to enhance drug discovery efficiency and expand treatment options for patients with immune-related conditions.
Funding
$24.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ICFounders
Product
Problem
Current drug discovery processes for autoimmune diseases are slow and inefficient, often resulting in limited treatment options for patients suffering from conditions like rheumatoid arthritis and atopic dermatitis. Traditional chemical synthesis methods can be time-consuming and may not explore a diverse range of potential therapeutic compounds.
Solution
DeepCure is developing small molecule therapies for autoimmune diseases using its Inspired Chemistry™ platform, which automates chemical synthesis to accelerate drug discovery. This platform enables the rapid creation and testing of a wide array of chemical compounds, increasing the efficiency of identifying potential drug candidates. By focusing on immune-related conditions and collaborating with leading researchers, DeepCure aims to expand the availability of effective treatments for patients. Their lead development candidate, DC-9476, targets multiple autoimmune diseases, including rheumatoid arthritis.
Target Audience
The primary target audience includes patients suffering from autoimmune diseases such as rheumatoid arthritis, atopic dermatitis, asthma and COPD, as well as the researchers and clinicians who treat these conditions.
Features
- Inspired Chemistry™ platform for automated chemical synthesis
- Focus on small molecule therapies
- Lead development candidate DC-9476 targeting multiple autoimmune diseases
- Collaboration with researchers at the Leeds Institute of Rheumatic and Musculoskeletal Medicine
- STAT6 transcription factor program for atopic dermatitis, asthma and COPD